Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma.

MLA

Pham, Thao D., et al. “Regorafenib Induces DNA Damage and Enhances PARP Inhibitor Efficacy in Pancreatic Ductal Carcinoma.” BMC Cancer, vol. 24, no. 1, Dec. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12885-024-13334-y.

APA

Pham, T. D., Becker, J. H., Metropulos, A. E., Mubin, N., Spaulding, C., Bentrem, D. J., & Munshi, H. G. (2024). Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma. BMC Cancer, 24(1), 1–12. https://doi.org/10.1186/s12885-024-13334-y

Chicago

Pham, Thao D., Jeffrey H. Becker, Anastasia E. Metropulos, Nida Mubin, Christina Spaulding, David J. Bentrem, and Hidayatullah G. Munshi. 2024. “Regorafenib Induces DNA Damage and Enhances PARP Inhibitor Efficacy in Pancreatic Ductal Carcinoma.” BMC Cancer 24 (1): 1–12. doi:10.1186/s12885-024-13334-y.